We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sanofi and Regeneron Give Up on Kevzara for COVID-19 After Phase 3 Flop

Sanofi and Regeneron Give Up on Kevzara for COVID-19 After Phase 3 Flop

September 2, 2020

Sanofi and Regeneron Pharmaceuticals said they have no plans to conduct further trials of their rheumatoid arthritis drug Kevzara for COVID-19 after it failed in a late-stage study.

The phase 3 trial tested 200-mg or 400-mg doses of Kevzara (sarilumab) vs. a placebo in 420 severely or critically ill COVID-19 patients. The benefits from the treatment, including shorter hospital stays and faster improvements in clinical outcomes, were not statistically significant, and some patients experienced serious adverse events, including pneumonia.

In July, the companies stopped a separate phase 3 U.S. trial of the immunosuppressive drug as a treatment for critically ill COVID-19 patients following disappointing results (DID, July 6).

Roche’s Actemra (tocilizumab), another rheumatoid arthritis treatment, was also found to have no benefit for hospitalized COVID-19 patients with severe pneumonia in a phase 3 trial. However, the drug is still in multiple mid- and late-stage trials for COVID-19, including as a  combination treatment with Gilead Sciences’ remdesivir (DID, July 30).

Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib) is also in phase 3 testing for hospitalized COVID-19 patients and is also under evaluation with remdesivir. Results of those trials have not yet been released (DID, June 16). — Jordan Williams

COVID-19

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • MicroPort Navibot Receives 510(k) Clearance for Its SkyWalker System

  • FDA Expands Approval of Pfizer and Myovant’s Myfembree to Include Endometriosis

  • FDA Provides Update on Haimen Shengbang Laboratory’s Recall of Its Viral Transport Media Containers

  • FDA Issues EUA for Monkeypox Vaccine

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing